Vitravene 250mg Capsule strip of 10 capsules

Vira-G Eye Gel is used in the treatment of Cytomegalovirus Infection.

Ganciclovir 250mg

It is not known whether it is safe to consume alcohol with Vitravene 250mg Capsule. Please consult your doctor.

Vitravene 250mg Capsule may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.

ull,

Ganciclovir : Headache, Dizziness, Vomiting, Nausea, Fatigue, Fever, Stomach pain, Diarrhea, Skin rash

Vitravene 250mg Capsule is to be taken with food.

Vira-G Eye Gel is an antiviral medication which treats viral infections of the eye. It works by preventing the multiplication of the virus on the surface of your eyeball (cornea). This stops the production of new viruses and clears up your eye infection.

Q. Is Vira-G a vesicant/ antibiotic?
No, Vira-G is not a vesicant/ an antibiotic

Q. Is Vira-G?
Yes, Vira-G is dialyzabl

Q. Is Vira-G a chemotherapy drug?
Yes, Vira-G is a chemotherapy used for the treatment of viral infections. Do not confuse it with chemotherapy or chemo drugs used for the treatment of cancer

Q. Is Vira-G nephrotoxic?
Yes, Vira-G is known to have nephrotoxicity (toxic to kidneys)

Q. Is ganciclovir a protease inhibitor?
No, ganciclovir is not a protease inhibitor; it belongs to synthetic nucleoside analogues class of antivirals

Q. Does Vira-G cover hsv (hepes simplex virus)?
Yes, Vira-G may be used to treat hsv (hepes simplex virus)

Q. How does Vira-G cause myelosuppression?
Vira-G is directly toxic to colony forming stem cells inside bone marrow which is responsible for RBCs, WBCs and platelets formation, thereby causing myelosuppression.

Vitravene 250mg Capsule may cause side effects which could affect your ability to drive.
You may feel sleepy, dizzy, confused or shaky, or you may lose your balance or have fits while using Vitravene 250mg Capsule.